Introduction
Materials and methods
Study design
Indication for PVR
Surgical technique
Cardiac magnetic resonance imaging
Follow up
Definitions
Statistics
Results
Patient population
Age (years) | 32 ± 12 |
Sex (female) | 4 (40) |
Body surface area (m2) | 1.9 ± 0.2 |
Body mass index (kg/m2) | 26 ± 5.5 |
Any cardiac medication | 1 (10) |
Diabetes mellitus | 0 |
Hypertension | 0 |
Current smoker | 0 |
No of previous interventions | 1.5 ± 0.5 |
History of arrythmia | 0 |
NYHA class | |
I | 8 (80) |
II | 2 (20) |
Laboratory values | |
S-creatinine (μmol/L) | 64 ± 16 |
B-Haemoglobin (g/L) | 144 ± 11 |
Surgical correction for TOF | 6 ± 9 |
Age at primary correction (years) | |
Previous palliative shunt | 4 (40) |
BT-shunt |
Intra- and postoperative data
Type of conduit | |
Epic bioprosthetic mitral valve conduit | 5 (50) |
RVOT Elan bioprosthetic heart valve conduit | 5 (50) |
Pulmonary valve replacement | |
Perfusion time (min) | 85 ± 20 |
Aortic cross-clamping (min) | 7 ± 15 |
Lowest temperature (°C) | 35 ± 1 |
Previous interventions | |
PA-homograft | 3 (30) |
LPA-stent | 1 (10) |
Palliative procedures | |
BT-shunt | 4 (40) |
Time since last intervention (years) | 20 ± 14 |
Time since total correction | 27 ± 11 |
Complications | 1 (10) |
Arrhythmia | |
New onset SVT | 1 (10) |
Infection | 1 (10) |
Pre-sternal | 0 |
Heart failure | 1 (10) |
Myocardial infarction | |
Other complications | 10 ± 4 |
Postoperative hospitalization (days) | |
Duration ICU stay (days) | 1 ± 0 |
Hemodynamic data
Variables (n = 10) | Before PVR | After PVR |
Students t-test
|
Wilcoxon Signed Rank Test
|
---|---|---|---|---|
RVEDV (ml) | 309 ± 85 | 231 ± 45 | 0.001 | 0.005 |
RVEDVI (ml/m2) | 161 ± 33 | 120 ± 23 | < 0.001 | 0.005 |
RVESV (ml) | 171 ± 58 | 136 ± 40 | 0.043 | 0.047 |
RVESVI (ml/m2) | 89 ± 25 | 71 ± 21 | 0.036 | 0.047 |
RVSV (ml) | 138 ± 45 | 95 ± 13 | 0.006 | 0.005 |
RVSVI (ml/m2) | 72 ± 20 | 50 ± 6 | 0.002 | 0.005 |
RVEF (%) | 46 ± 11 | 42 ± 9 | 0.337 | 0.373 |
LVEDV (ml) | 149 ± 22 | 171 ± 28 | 0.002 | 0.007 |
LVEDVI (ml/m2) | 79 ± 10 | 90 ± 15 | 0.012 | 0.015 |
LVESV (ml) | 68 ± 17 | 76 ± 20 | 0.213 | 0.236 |
LVESVI (ml/m2) | 36 ± 8 | 40 ± 11 | 0.271 | 0.284 |
LVSV (ml) | 81 ± 12 | 95 ± 12 | < 0.001 | 0.005 |
LVSVI (ml/m2) | 43 ± 7 | 50 ± 6 | 0.001 | 0.005 |
LVEF (%) | 55 ± 7 | 56 ± 6 | 0.656 | 0.593 |
PI (%) | 49 ± 11 | 1 ± 1 | < 0.001 | NA |
MPA netflow (mL/min) | 5100 ± 1500 | 6100 ± 800 | 0.120 | 0.139 |
Discussion
Clinical implications
Limitations
Conclusion
Acknowledgements
Funding
Availability of data and materials
Ethics approval and consent to participate
Consent for publication
-
This manuscript is not currently under consideration, in press or published elsewhere.
-
This manuscript is truthful original work without fabrication, fraud or plagiarism.